Intravenous immunoglobulin enhances the killing activity and autophagy of neutrophils isolated from immunocompromised patients against multidrug-resistant bacteria
Adult
Male
0301 basic medicine
Neutrophils
Primary Cell Culture
Hematopoietic Stem Cell Transplantation
Immunoglobulins, Intravenous
Microbial Sensitivity Tests
Middle Aged
Coculture Techniques
Anti-Bacterial Agents
3. Good health
Immunocompromised Host
03 medical and health sciences
Superoxides
Drug Resistance, Multiple, Bacterial
Hematologic Neoplasms
Pseudomonas aeruginosa
Autophagy
Escherichia coli
Humans
Female
Immunosuppressive Agents
DOI:
10.1016/j.bbrc.2015.06.004
Publication Date:
2015-06-25T19:11:47Z
AUTHORS (10)
ABSTRACT
Intravenous immunoglobulin (IVIG) is periodically administered to immunocompromised patients together with antimicrobial agents. The evidence that supports the effectiveness of IVIG is mostly based on data from randomized clinical trials; the underlying mechanisms are poorly understood. A recent study revealed that killing of multidrug-resistant bacteria and drug-sensitive strains by neutrophils isolated from healthy donors is enhanced by an IVIG preparation. However, the effectiveness of IVIG in immunocompromised patients remains unclear. The present study found that IVIG increased both killing activity and O2(-) release by neutrophils isolated from six patients receiving immune-suppressive drugs after hematopoietic stem cell transplantation (HSCT); these neutrophils killed both multidrug-resistant extended-spectrum β-lactamase-producing Escherichia coli (E. coli) and multidrug-resistant Pseudomonas aeruginosa (P. aeruginosa). Moreover, IVIG increased the autophagy of the neutrophils, which is known to play an important role in innate immunity. These results suggest that IVIG promotes both the killing activity and autophagy of neutrophils isolated from immunocompromised patients against multidrug-resistant bacteria.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (18)
CITATIONS (19)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....